On Demand 2026 Sunday PM General Sessions

This course contains the following sessions from Sunday's afternoon program:

  • Jeopardy! What's That Rash?
  • The Precision Era: Navigating Pediatric Asthma
  • Venom Immunotherapy: Bridging Evidence and Practice in the 2026 Parameter Update
  • Advocating for Access to Biologic Therapies in Allergy & Immunology: Science, Policy and Practical Strategies
  • Drug Allergy Across the Spectrum: Practical Evaluation and Management
  • AI Tools for the Practicing Allergist
  • Chronic Rhinosinusitis: Tailored Approaches for Patients With and Without Nasal Polyps
  • Editor’s Choice: Best Articles from Annals of Allergy, Asthma & Immunology

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 12.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Identify the hallmark clinical features, biomarkers, and inflammatory pathways that define T2 high asthma in children.
  • Select the appropriate treatment based on biomarkers, exacerbation risk, and patient characteristics.
  • Recognize diagnostic challenges and implement treatment strategies for children who do not fit the T2-high pattern.
  • Apply updated diagnostic reasoning strategies to interpret discordant or complex test results, utilize component testing and biomarkers appropriately, and design streamlined diagnostic workflows that accommodate local resources.
  • Identify appropriate candidates for VIT using updated risk-stratification guidance; select optimal dosing and build-up schedules (conventional, rush, ultrarush); and determine appropriate maintenance intervals and duration of therapy, including when extended or indefinite VIT is indicated.
  • Apply parameter-informed approaches to safely manage high-risk populations including those with mast cell disease, elevated baseline tryptase, and medication comorbidities; integrate shared decision-making pathways for patients with atypical presentations; and implement practical strategies to improve VIT adherence and optimize clinic workflows.
  • Cite comparative effectiveness and real-world outcomes of biologics in asthma, AD and NP and new emerging pathways.
  • Identify key elements of high-quality documentation PA templates and supporting clinical evidence, appeal letter musts and avoiding coding pitfalls.
  • Engage state societies and coalitions, using clinical data to advocate with insurers and employers and sharing success stories.
  • Explain biologic value to patients, navigating patient assistance, co-pay programs, and affordability resources, mitigating disparities in biologic access.
  • Apply evidence-based risk stratification and testing approaches to evaluate and delabel antibiotic allergy in special populations (young children, pregnant women and the perioperative setting).
  • Differentiate NSAID hypersensitivity phenotypes, review diagnostic strategies, including oral challenge protocols, and review management approaches including aspirin desensitization when indicated. Develop evaluation and management strategies for suspected drug allergy in complex inpatient and specialty care settings.
  • Recognize and initiate appropriate management of severe cutaneous adverse drug reactions, including Stevens–Johnson syndrome, toxic epidermal necrolysis, DRESS, and AGEP. Highlight emerging insights into pharmacogenomics, cross-reactivity, acute management, and long-term monitoring.
  • Identify current and emerging AI tools for clinical documentation and gain hands-on experience with ambient dictation services.
  • Gain experience with AI tools that help clinicians access high-quality, evidence-based insights, translate those findings into practical clinical decisions, and support the development of effective patient education resources.
  • Recognize emerging AI solutions that optimize administrative workflows, improve scheduling efficiency, and automate revenue cycle management and prior authorization.
  • Focus on the epidemiology, pathophysiology, clinical phenotypes of CRSwNP vs CRSsNP and explore the role of biomarkers in predicting treatment response.
  • Describe current biologic therapies for CRSwNP, including indications, patient selection, and expected outcomes; summarize adjunctive medical treatments such as intranasal and systemic corticosteroids; and identify scenarios in which surgical intervention is appropriate.
  • Identify evidence-based medical therapies for CRSsNP and indications for endoscopic sinus surgery and post-surgical management strategies.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary

Available credit: 
  • 12.50 AMA PRA Category 1 Credit™
  • 12.50 Attendance
  • 12.50 CBRN
Course opens: 
11/24/2026
Course expires: 
12/31/2027
Rating: 
0

Travis A. Miller, MD, FACAAI
Luz S. Fonacier, MD, FACAAI
Stephanie L. Mawhirt, DO, FACAAI
Peter A. Lio, MD, FAAD
Angela D. Hogan, MD, FACAAI
Suzanne Y. Ngo, MD, FACAAI
William C. Anderson, III, MD, FACAAI
Daniel J. Jackson, MD, FACAAI
James M. Tracy, DO, FACAAI
Amber Hardeman, MD, MPH, MBA
Karla Adams, MD, FACAAI
David BK Golden, MD, FACAAI
Jeremy C. McMurray, MD
Jared Darveaux, MD, FACAAI
J. Wesley Sublett, MD, MPH, FACAAI
Priya J. Bansal, MD, FACAAI
Vivek U. Rao, MD, FACAAI
Gregory W. Bensch, MD, FACAAI
Bryan L. Martin, DO, FACAAI
David A. Sanchez, MD, FACAAI
Samantha R. Horn, MD
Kimberly G. Blumenthal, MD, MSc, FACAAI
Anna R. Wolfson, MD, FACAAI
Aleena Banerji, MD, FACAAI
Elizabeth J. Phillips, MD
Stanley H. Cheng, DO
Fatima S. Khan, MD, FACAAI
Eric M. Schauberger, DO, PhD, FACAAI
Nicole M. Chase, MD, FACAAI, FAAP
William E. Berger, MD, MBA, FACAAI
Andrew A. White, MD, FACAAI
Anju T. Peters, MD
Joseph K. Han, MD
Mitchell H. Grayson, MD, FACAAI
Larry Borish, MD, FACAAI
Donald Y M Leung, MD, PhD, FACAAI
Anna H. Nowak-Wegrzyn, MD, PhD, FACAAI

Available Credit

  • 12.50 AMA PRA Category 1 Credit™
  • 12.50 Attendance
  • 12.50 CBRN
Please login or create an account to take this course.